MM-111 first-in-human phase 1/ 2 and pharmacologic study in patients with advanced refractory HER2-Positive (HER2+) cancers. MM-302 pre-clinical safety and activity study of anthracycline delivery to HER2-Positive (HER2+) tumors
The trial, enrolling patients at multiple centers across the United States, is part of a broad Phase 2 program for MM-121 launched by Merrimack and sanofi-aventis this year